Aclaris Raises $59.8M, Holds $190.8M Cash; ATI-052 Shows 45-Day Half-Life
Aclaris ended Q1 with $190.8 million in cash, equivalents and securities, up from $151.4 million at year-end, after raising $59.8 million in an 18.4 million-share offering. Phase 1a ATI-052 data showed a 45-day half-life and sustained target engagement through week 20, underpinning a three-month dosing potential.
1. ATI-052 Phase 1a Results
Full top-line data from single and multiple ascending dose cohorts showed ATI-052 achieved an estimated half-life of approximately 45 days and delivered complete target inhibition through week 20 for TSLP and week 12 for IL-4, supporting a potential every-three-month dosing regimen and demonstrating a favorable safety profile.
2. Ongoing and Upcoming Clinical Milestones
Aclaris is dosing two Phase 1b proof-of-concept trials of ATI-052 in atopic dermatitis and asthma with topline results due in the second half of 2026, plans a Phase 2b program for ATI-052 in asthma in late 2026, and expects Phase 2 bosakitug and IND filing for ATI-9494 in the second half of 2026.
3. ATI-2138 Phase 2a Data
Additional Phase 2a results in lichen planus showed a 70 percent improvement in body surface area involvement, 50 percent itch reduction, 55 percent improvement in POEM severity scores and a 65 percent gain in dermatology quality-of-life index.
4. Financial Position and Runway
In Q1, the company raised $59.8 million through an 18.4 million-share offering and ended March with $190.8 million in cash, cash equivalents and marketable securities, providing a runway expected to support clinical programs through 2028.